The authors have conducted an analysis to validate a computer model that uses age-specific human immunodeficiency virus (HIV) prevalence data to estimate age-specific HIV incidence rates. Data for the analysis are from a cohort study of volunteer male workers in Bujumbura, the capital city of Burundi. Testing for HIV prevalence was conducted at baseline, and HIV-negative subjects were retested annually from 1990 to 1993 to determine rates of seroconversion. Input parameters required for the model include age-specific HIV prevalence and estimates of age-specific mortality rates for HIV-negative and HIV-positive subjects. Incidence rate estimates from the model were 2.0. 2.7, 1.0, 1.5, and 1.8 per 100 person-years for age groups 20-24, 25-29, 30-34, 35-39, and 40-44 years, respectively. Corresponding observed incidence rates for the same age groups were 1.6,1.8, 2.2, 2.3, and 1.5 per 100 person-years, respectively. Most observed incidence rates fell within the 95% confidence limits of the model estimates. Expected numbers of cases within age intervals did not differ significantly from observed numbers of cases. The authors conclude that the model proved to be successful in approximating observed incidence rates and that it is a useful tool, particularly in countries where prevalence data are available and where HIV prevalence has stabilized, which is when the underlying assumptions in the model are best met. The model provides crucial information about incidence rates that might not be evident from prevalence data alone. Am J Epidemiol 1996;144:214-23. cohort studies; developing countries; HIV seropositivity; HIV seroprevalence; incidence; models, statistical Human immunodeficiency virus (HTV) seroprevalence surveys in sentinel populations are used in many developing countries to monitor the acquired immunodeficiency syndrome (AIDS) epidemic. Although seroprevalence data can be useful for planning purposes, they do not provide a measure of HTV incidence rates. In addition, because changing incidence rates can be consistent with stable prevalence over time, the Received for publication April 6, 1995, and accepted for publication January 5, 1996.
threat of persistently high infection rates may not be readily apparent to project planners and policy makers who do not otherwise have access to incidence data (1) (2) (3) (4) (5) . Although direct measurement of incidence through cohort studies is possible, recent articles such as those by Brookmeyer and Quinn (6) and Heyward et al. (7) have discussed the logistical and methodological difficulties of estimating incidence rates (including the complications of tracking large numbers of people and the degree of randomness of subjects lost to follow-up), and have referred to possible uses of seroprevalence data in this regard. It is important, therefore, to assess the ability of these indirect methods to provide information about incidence rates. Some of the main methods that have been proposed include: 1) use of HTV seroprevalence surveys to estimate past HTV infections; 2) back-calculation, which uses reported AIDS cases to reconstruct historical infection rates; and 3) the birth cohort method, which uses the slopes of trend lines from repeated samples of birth cohorts to make crude estimates of HTV incidence (2, (7) (8) (9) .
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The analysis presented here is a validation of a model from class 1 above, which was developed by Leske et al. (10) , Podgor et al. (11) , and Podgor and Leske (12) to estimate age-specific incidence rates from prevalence data. The advantage of this method is that it uses data from a single cross-sectional survey to estimate HTV incidence. The model is particularly appropriate for developing countries, where prevalence data are more readily available than reliable AIDS case data (8) . Leske et al. (10) demonstrated the model for common eye conditions such as glaucoma and diabetic retinopathy, but it is generally applicable for conditions that are irreversible.
MATERIALS AND METHODS The population
From 1990 to 1993, male workers from five largeand medium-sized companies in Bujumbura, the capital city of Burundi, were invited to participate on a voluntary basis in a longitudinal study to determine the annual incidence rate of human immunodeficiency virus type 1 (HTV-1) infection. Recruitment occurred annually in May 1990, August 1991, and August 1992 and lasted for a period of approximately 2 months each time. Subjects were tested for HTV-1 antibodies at the time of recruitment and those who were HTV-1-negative were retested yearly. HTV testing was done using the Genetic Systems enzyme-linked immunoadsorbent assay (ELISA) for HTV-1 with confirmation by Genetic Systems Pageblot HTV-1 (Genetic Systems, Seattle, Washington). The availability of both incidence and prevalence data from the same population allows for the direct estimation of HTV incidence as well as incidence estimation through the model.
THE MODEL
The model, which estimates age-specific incidence from prevalence, was tested using data from subjects recruited in 1990, the year of the largest recruitment. Incidence estimates were calculated using a spreadsheet based on the method described by Podgor et al. (12) . The estimated incidence is derived by solving an equation that uses estimated prevalence of disease at the beginning and end of an age interval and known age-specific mortality rates during the interval. The model is based on the functional relation between a risk (CI) and a rate (ID) that:
can also be represented by age differences) between the beginning and end of an interval. This relation is true under the assumption that the incidence rate (density) remains constant (13 
where P o is the prevalence at the beginning of the interval, P x is the prevalence at the end of the interval, Aj is the death rate among disease-free individuals, A 2 is the disease incidence rate, and A 3 is the death rate among individuals with the disease. Once the incidence rate is obtained, it is divided by the number of years in the age interval to obtain an annual rate.
Model assumptions.
The model makes the assumptions that 1) HTV infection is lifelong and irreversible, 2) HTV-infected and non-infected individuals may have differential mortality rates that are assumed to be constant throughout the interval under consideration, and 3) the disease incidence and population composition with respect to risk factors for disease remain constant during the time period being analyzed.
Validation
The model estimates were validated with observed incidence rates that were calculated with data from seronegative subjects who entered the study in 1990 and who had one or more follow-up HIV tests. For consistency with the model, observed incidence rates were calculated by converting age-specific risks to rates. Specifically, the CI observed during the study in each age group was calculated using equation 3 (13):
where ID is incidence density, CI is the cumulative incidence or risk, and Af is the elapsed time (which = i -na - (3) where t represents the specific time interval of follow-up and j is the total number of years of followup. (Subjects were followed for 3 years (y = 3). Interval-specific risks were calculated for each year (f O -i = 90-91, t x _ 2 = 91-92, and/ 2 _ 3 = 92-93).) The CI is then converted to a rate through the backwards use of equation 1, (A 2 = -ln(l -CI)), which is then divided by j to obtain annual incidence rates.
The assumptions used in the incidence calculations were: 1) that men who were lost to follow-up did not differ significantly from those who were followed in terms of demographic variables or their risk of becoming HTV infected, and 2) that seroconversion between HTV screenings occurred at a constant rate.
Definitions
Model data. To estimate incidence rates, the model was applied to age-specific prevalence data for each age interval. Specifically, the following input parameters were required: 1) age-specific prevalence at the beginning of the age interval (P o ) and at the end of the age interval (Pj), 2) sample size used to estimate P o and P] (N o and N{), 3) age-specific mortality rates for HIV-negative individuals, and 4) age-specific mortality rates for HIV-positive individuals.
Smoothing of prevalence data. The age-specific point prevalence curve was irregular, so the data were smoothed by the use of moving averages to avoid some of the large variation in incidence estimates. This was done by using the age-specific prevalence for an n-year age interval to estimate the point prevalence at the midpoint of the age interval. Age-specific model estimates were done for 3-and 5-year age intervals so, for example, for 5-year intervals, to estimate the annual incidence rate for 20-25 year-olds, the point prevalence for 20 year-olds (P o ) was estimated by the prevalence for the group of subjects who were 18-22 years-old and the point prevalence for 25 year-olds (P,) was estimated by the prevalence for the 23-27-year-old group. N was the sample size for the n-year age group used to calculate the prevalence. Annual incidence rates were obtained by dividing the final result by the number of years in the interval.
Calculation of observed incidence rates. The observed incidence rates were calculated to correspond to model requirements, i.e., they were computed for the 3-or 5-year age groups between the two prevalence points used in the model. For example, the corresponding observed incidence rate for the 20-24 year-old interval used in the model was that observed in 20-24-year-old men during the follow-up period.
Mortality rates for HIV-negative males. The demographic data for computing mortality rates in Burundi are not readily available, therefore indirect estimates provided by the US Bureau of the Census were used (Peter Way, US Bureau of the Census, personal communication, 1994). These estimates were produced in association with the Census Bureau's population projections for Burundi and were based on life expectancy estimates obtained from the 1987 Demographic and Health Survey for Burundi. The estimates were very similar to those obtained in a study of estimates of adult mortality in Burundi (14) . While these estimates may not be completely accurate, the model is fairly robust with respect to mortality rates among the HTVnegative, and small changes in the mortality rates did not affect the incidence estimates.
Mortality rates for HIV-positive males. Estimates of mortality rates for HIV-positive males in Burundi were not available. As a substitute, the estimated average annual percent of HIV-positive men diagnosed with AIDS was added to the baseline mortality rate for HIV-negative men to provide an estimate of the mortality rate among HIV-positive men. The rationale for using progression to AIDS instead of mortality is that this is a population of factory workers being sampled at their place of work. Because the men are likely to stop working when they become seriously ill with AIDS, they will disappear from the sample when they develop AIDS as opposed to when they die.
Estimates of incubation times for HTV seroconversion to AIDS diagnosis were based on published incubation distributions from other populations. In a review article of studies that estimated the incubation period of HTV (15) , the studies with the fewest methodological problems in terms of selection bias and knowledge of when seroconversion occurred were the ones conducted on intravenous drug users (TVDU) in Italy. These studies provided the age-specific estimates of median times from seroconversion to AIDS on which the progression rates used for this analysis were based. It is difficult to know whether these estimates are appropriate for Burundi, because there is reason to believe that median incubation periods may be shorter in developing countries. However, it should be noted that Alcabes et al. (15) studied a variety of populations across geographic, economic, and temporal strata, and they found remarkably similar incubation distributions. The rates used in the model do not differ greatly from those reported in other studies from Central Africa (16) . 426 in 1991, and 393 in 1992. Follow-up data from seronegative men aged 20-45 years recruited in 1990 were used to calculate the observed incidence rates for the analysis. A total of 1,049 men fell into this category. These men were followed for a total of 1,635 person-years between 1990 and 1993. Table 1 compares baseline characteristics of men who were retested versus men who were lost to follow-up. Approximately 38 percent of seronegative men were lost to follow-up in the first year and an additional 10 percent and 6.6 percent in the second and third years, respectively. There was no difference in baseline distributions of men who were followed compared with men who were not followed with regard to age, marital status, or history of urethritis or genital ulcer disease (GUD), except during the first year (1990-1991), when men over age 38 years and married men were more likely to be lost to follow-up, and during the last year (1992-1993), when men who had reported an occurrence of GUD in the prior year were less likely to return for follow-up testing than those who did not. The difference in the rate of dropout by age should not affect the results, because the incidence estimates are stratified by age. The difference in marital status can be explained by age confounding, which again is controlled in the analysis. Data on reported sexually transmitted diseases (STDs) were unavailable for the first year (1990-1991), but in the subsequent 2 years, men who had reported an episode of urethritis in the preceding year were no more or less likely to drop out than men who did not. The same was true of GUD disease in the second year, but not in the third year, as mentioned. Reported episodes of GUD have been shown to be associated with HTV seroconversion in these data as well as in other studies on men (17) (18) (19) . Therefore, the tendency for men with a history of GUD to drop out of the study raises the possibility that the observed incidence rates could be underestimated for this population. Sample sizes of men with GUD were very small, so these differences could be a result of random error.
The men who dropped out are assumed to have had the same likelihood of seroconverting as the men who remained in the study. The unknown degree of response bias is an internal validity problem that could affect the accuracy of the point estimates from the study sample, and the effect of this potential bias on validation of the model is difficult to quantify. Brookmeyer et al. (20) found that follow-up bias can cause significant misrepresentations in HTV incidence rates. Their findings were based on a method that used prevalence of p24 antigenemia in seronegative or indeterminate subjects from a cross-sectional survey. In the present case, the effects of this bias are likely to be minimal because the difference occurred only in the third year when the smallest amount of person-time was contributed.
Age-specific prevalence trends Table 2 presents smoothed and unsmoothed HTV prevalence figures and sample sizes for the 1990 cohort. The prevalence of HTV followed a clear upward trend by age ranging from zero percent in men under age 20 years to over 20 percent in men over age 40 years. The prevalence data were smoothed for 3-and 5-year age intervals so that the model could be tested for longer and shorter intervals.
Prevalence over time
In the absence of incidence data, prevalence data over time are frequently used by health planners to document trends in the AIDS epidemic. The HIV prevalence at baseline for the 2,073 new volunteers who entered the cohort in 1990, 1991, and 1992 were compared using the 5-year age categories that were used in the model (data not shown). The change in prevalence in new recruits over time was not statistically significant in any of the age categories except the 33-37 year-olds (x 2 = 6.58, p = 0.04). The prevalence among new recruits in this age group rose from 17 percent in 1990 to 25 percent in 1991, and dropped to 8 percent in 1992, which illustrates Validation of a Method to Estimate Age-specific HIV Incidence Rates 219 the degree to which these values can fluctuate due to random error. The prevalence for the entire group went from 14 percent in 1990 to 13.6 percent in 1991 to 13 percent in 1992 (x 2 = 0.29, p = 0.86), indicating stable prevalence over time.
Comparison of model estimates and observed cohort incidence rates Table 3 presents smoothed prevalence data for 5-year age intervals, along with sample sizes, and mortality estimates used in the model to calculate age-specific incidence rates for the 1990 prevalence data. Model incidence estimates and observed incidence rates and their standard deviations are presented as well. Standard deviations for model estimates were calculated based on the "delta method" described by Podgor and Leske (12) (see appendix in Podgor and Leske (12) for details on the formulas used). The standard deviations for the observed rates are approximated with the standard formula for the variance of proportions. Model estimates of age-specific incidence rates ranged from 1.0 to 2.7 per 100 person-years. Observed incidence rates ranged from 1.5 to 2.3 per 100 person-years. The incidence estimates mimicked the prevalence curves, with sharply increasing slopes corresponding to higher incidence rates and more moderately increasing slopes corresponding to lower incidence rates.
The model is very sensitive to the difference between the beginning and ending prevalence in the interval, which is why it is important to smooth the data. An unsophisticated observer might assume that a level prevalence means that older men had a negligible or very low incidence, which is not at all the case. The model provides estimates that suggest that older men have only slightly lower incidence rates than younger men. The actual cohort data confirm: 1) that die incidence rates in older men are high, and 2) that they can even be higher than the rates in younger men.
Sensitivity analysis
Smoothing. When 3-year intervals are used, there are greater fluctuations in prevalence due to smaller sample sizes (table 4). The model estimates follow a roller coaster pattern, corresponding to the prevalence curve, which has sharply increasing and decreasing slopes. The incidence estimates corresponding to the falling part of the curve are probably artificially low and visa versa. This observation is verified by comparing the model estimates to the more constant cohort estimates. In addition, if unsmoothed prevalence data are used, the incidence estimates vary even more in response to random fluctuations in the data.
AIDS progression rates. As noted above, the model is fairly robust with respect to mortality rates among HTV-negative subjects, A,, but is much more sensitive to changes in values of A 3 , the mortality rate among HIV-positive subjects. Age-specific progression rates for HIV-positive men are not available for Burundi; however, comparison of model estimates to observed incidence rates suggest that, in general, the model estimates were higher than the observed estimates in men under age 30 years and lower than observed estimates in men over age 30 years. Plausible explanations for this discrepancy are that progression rates do not remain constant with duration from infection and that younger men probably have been infected more recently.
There are two important cases where the difference in duration of infection and progression to disease are important to consider when using the model. The first is when there is a new, rapidly growing epidemic, and mortality is still low in all age groups. When this is the case, seroprevalence usually increases rapidly in all * No., number of subjects used to calculate the prevalence. t Prevalence is for this 5-year interval centered around the given age. t Incidence rate is for the 5-year interval between the two prevalence points used in the model. § Incidence rate with standard deviation in parentheses. 1.0)  3.0(1.3)  2.4(1.8)  0.2(1.8)  0.2(1.9)  4.1 (3.1)  1.1 (3.6 2.4 (1.5) (n-96) 3.5 (3.2) (n -34) * No., number of subjects used to calculate the prevalence. t Prevalence is for the 3-year interval centered around the given age. i Incidence rate is for the 3-year interval between the two prevalence points used in the model. § Incidence rate with standard deviation in parentheses.
age groups. In the first few years of such an epidemic, before seroprevalence begins to stabilize, the crosssectional, age-specific analysis we describe here should not even be applied. Instead, data are needed from two points in time. In this situation, progression to AIDS and AIDS mortality are still quite low. Therefore, assuming similar samples and negligible migration, simply subtracting the prevalence at the first point in time from the prevalence at the second point in time gives a reasonable estimate of the incidence rate.
In the second case, when there is a relatively stable epidemic, there is usually a higher proportion of young people with recent infections. Virtually all HIV-positive 20-24 year-olds will have been infected within the past 5 years, and most of them probably within the past 3 years. However, among HIV-positive 30-34 year-olds, many of them will have been infected during their twenties, and thus the average duration of infection will be much greater. The sensitivity analysis presented in table 5 examines the possible bias from this source. It suggests that the second case is a likely scenario in Bujumbura, where the epidemic is older and relatively stable (21) . By assuming an average (constant) progression rate, our original analysis (column a) may have overestimated the progression rate in the first few years after infections, i.e., in the younger age groups. As illustrated in column c, model estimates matched the cohort study incidence rates better when it was assumed that HTV progressed more slowly for men under age 30 years and progressed faster for men over age 30 years. Validation of a Method to Estimate Age-specific HIV Incidence Rates 221
Comparison with EpiModel
For comparison purposes and because of its wide availability, age-specific incidence rates were also calculated with EpiModel, a software package developed at the World Health Organization (WHO) with the goal of making short-term projections of adult AIDS cases based on an estimate of the number of infected adults (22, 23 ). An early version of EpiModel was modified by Chin and his colleagues at WHO (at the suggestion of one of the present authors (DS)), so that it could show HTV incidence and prevalence rates.
EpiModel is a flexible spreadsheet type program. While it was not designed for the purpose of estimating age-specific incidence rates, we have shown that it can be successfully used for that purpose. When used to estimate incidence rates from prevalence data, its curve-fitting routine is not used, and the assumptions in the model are minimal. The time axis for EpiModel is intended to be used for calendar years, but it can also be used for years of age. The assumptions it uses in spreadsheet calculations are as follows. The default progression rate from HTV to AIDS has a 10-year median, with very slow progression during the first 3 years. EpiModel calculates progression from HTV infection to ADDS using a single progression rate for all ages. Table 6 compares the incidence estimates obtained from the two models to the observed values. Differences in the observed and expected number of HTV conversions within each age group were tested under the Poisson distribution. Expected numbers of conversions were calculated based on incidence rate estimates from the model. No significant differences were found in the Podgor and Leske model except in the 30-34 year-old age group. While this value is different from the observed rate, this should not be considered as evidence that the model is not working well. It is more likely due: 1) to a violation of the assumptions about stable incidence rates, 2) to a poor estimate of the mortality rate for that particular age group, or 3) to random variation. In the sensitivity analysis, when a higher mortality rate is used for the 30-34 years age group, the Podgor and Leske estimate is close to the actual rate.
Validation
EpiModel provides estimates that take account of the variation of incubation by time since infection. EpiModel gives slightly lower rates for 20-24 and 25-29 year-olds than Podgor and Leske's model (using our original assumption of average and constant progression rates), probably because most of these young men are relatively recently infected and thus are progressing more slowly to AIDS. Conversely, in the 30-34 years age group, EpiModel gives a slightly higher estimate of the HTV incidence rate because most of these men were infected in their twenties and are now at the peak period of their progression to AIDS, based on duration since infection. EpiModel estimates ranged from 1.3 to 2.3 for the different age groups and were also very close to the observed incidence rates. There were no statistically significant differences between the observed and expected number of seroconversions obtained with this model.
DISCUSSION
The objective of the study was to evaluate the usefulness of a model that uses HIV prevalence data from a one-time cross-sectional survey to estimate agespecific HTV incidence rates. Cross-sectional data, when viewed over time, appear to demonstrate that the epidemic is stabilizing and that the number of infected persons is not growing. However, examination of the incidence data indicates that the annual infection rate is quite high, roughly 2 percent per year. The results of our analysis suggest that the model developed by Podgor and Leske (12) can provide crude estimates of one-year age-specific incidence rates that are similar to those observed in longitudinal studies. The value of these estimates is that they inform policy makers about the rate at which people are currently becoming infected with HTV. This information is crucial because it can lead to conclusions about the level and direction of the epidemic that might be less readily apparent from the prevalence data alone.
Limitations
The model is subject to a number of limitations, the most obvious being the assumption of constant incidence rates. It was not possible to assess the constancy of the observed incidence rates over time by measuring changes in incidence during the follow-up period, because the number of seroconversions was too small. The degree to which violation of the constancy assumption may have affected model estimates is unpredictable and difficult to assess.
Either the Podgor and Leske-based spreadsheet or EpiModel can result in negative estimates of the incidence rates if prevalence at an older age is sharply less than at an earlier age. Such an estimate is obviously invalid, and indicates either of two things: 1) It may only indicate that the data set is too small, and has too much variability between the age groups used. In that case, pooling of age groups may resolve the problem.
2) It could indicate that the model assumptions do not hold in the age range being examined. For example, this could occur in a new epidemic if the incidence rates were very high among young women aged 15-24 years, but much lower among older women. Anomalous results could occur if an analysis were done in the first few years of such an epidemic, before younginfected women moved into the older age group. In this example, such an analysis could give a negative estimate of the incidence rate in the 25-29 years age group.
In addition, because HTV is an infectious disease with a high prevalence in Bujumbura, it stands to reason that over time the composition of the risk group will change as the population at risk becomes saturated with infection. Because the steady-state condition assumed by the model is only approximately met, the relation between prevalence, incidence, and duration that drives the model is approximate (24) and the model can produce only rough estimates.
Another limitation is the sensitivity of the model to changes in values of A 3 , the mortality rate in diseased subjects. Potential users of the model are advised to find the best available estimates of progression rates that apply to the study region and to try different rates that assume "faster" and "slower" progression. As is the case with all models, a range of values should be explored that portray the best and worst case scenarios. Duration of infection should also be considered when choosing appropriate mortality rates, particularly in terms of the degree to which the model assumption that mortality rates are assumed to be constant throughout the interval may be violated. The underlying assumptions of the model are best met in populations where prevalence has stabilized.
In addition to the limitations of the model, the cohort study itself has several limitations which limit the power of the validation analysis. These include the imprecision of the estimates due to the small number of seroconverters, the difficulty of following a large sample, and the distortions that could have resulted from response bias. However, it is precisely because of these sorts of difficulties in collecting cohort data, particularly in developing countries, that we are proposing this indirect approach to estimating incidence rates, which is also much less costly.
Finally, although the prevalence of HTV infection among adults in Bujumbura is quite high (approximately 15 percent) and can hardly be called a "rare" event, the incidence of new infections needed to maintain this high prevalence is still small enough that it is difficult to obtain precise incidence estimates. This was true for both the model estimates and the observed incidence rates. Therefore, it must be concluded that although the model is very useful for approximating the incidence rate of HTV infection, it should not be used to measure changes in incidence rates over time or differences in incidence rates between risk groups (e.g., to evaluate intervention programs), unless the samples are sufficiently large. On the other hand, the model can be very useful for improving estimation of sample sizes needed for longitudinal studies.
Conclusion
This model is very useful for providing "gross approximations of true incidence rates," the use for which it was intended when the model was first described by Leske et al. (10) . These estimates provide vital information about the rate of new HTV infections to health planners and policy makers that might not be evident from prevalence data alone. The model produced incidence estimates that were similar to those observed in the cohort study, providing evidence that the model is valid for estimation of incidence rates, particularly in countries where HTV prevalence has stabilized. Most importantly, the method may be used to remind planners and policy makers about the dynamics of the epidemic and help dispel the persistent misunderstanding that a stable seroprevalence means that no new infections are occurring and that the epidemic is "under control."
